Business Wire

IL-PRICEFX

Share
Pricefx Continues Its Momentum in 2019, Earning Top Honors and Delivering Strong Performance

Pricefx , the global leader in cloud pricing software, today announced another year of tremendous growth during its fiscal year ending December, 31, 2019. The company has grown by 85% on average each year for the last four years – 3 to 4 times the industry standard for pricing companies. As a result, Pricefx is continuing to expand its market share, particularly in the U.S. where the company more than doubled its total revenue.

Market Demand and Customer Wins

Gartner Inc. included Pricefx in the Magic Quadrant for Configure, Price and Quote Application Suites , as well as the Hype Cycle for CRM Sales Technology, 2019 as a Sample Vendor of Price Optimization and Management for B2B. The latter report states, “price optimization and management is close to the Plateau of Productivity because it is able to demonstrate quantifiable and tangible improvements in margin and revenue in successful implementations.”

Additionally, Gartner’s Market Guide for B2B Price Optimization and Management Software for 2019 includes Pricefx and states that it expects “the PO&M market to continue to grow rapidly during the next three years” and that “PO&M software has a rapid payback on investment (often less than six months).”

Pricefx currently has more than 100 customers across 37 countries, which include some of the largest manufacturing, retailing and energy businesses in the world. In 2019, Pricefx signed nearly 20 new enterprise customers with revenue in excess of $2 billion. New customers include Lyreco, Phillips 66, Scotts-Miracle Gro and Watsco.

Company Expansion

To scale for the rising demand of its easy-to-use pricing solutions, Pricefx also expanded its footprint in North America. The company more than doubled its headcount, adding 140 new employees in 2019.

In November 2019, Pricefx closed its Series B financing round with a total of €48 million in its coffers, which will be used to fuel the company’s continued market expansion and product development. On the heels of this latest funding, the company’s valuation has nearly tripled in the last twelve months.

Product Accolades and Advancements

Last year, Pricefx became the first solution provider to achieve Gold-Level Status for SAP® PartnerEdge® Build. The company also secured the highest rating on G2 Crowd for enterprise-grade pricing software. Pricefx won Product of the Year in the 2019 Sales and Marketing Technology awards (SAMMYs), the only pricing solution to do so, and was named the Gold winner in Enterprise Product of the Year - Sales Software.

The 2019 SaaS Awards program named Pricefx a finalist in the category “Best SaaS Product for Sales / Marketing” and the company was named a Bronze winner for Cloud Computing/SaaS Product or Service for Sales by the Customer Sales & Service World Awards .

Pricefx also completed its evolution to an enterprise-grade platform , announcing that subscribers of the company’s core SaaS product offerings receive full access to the entire platform feature set for no additional cost. By including the platform with core product subscriptions, Pricefx further lowered the total cost of ownership for its customers.

The fall product release brought forth Unity UI , a sleek, modern, intuitive user interface. Unity represented the first major UI update for Pricefx since its initial launch and dramatically improved the ease of use, consistency and responsiveness of Pricefx to create a better user experience on multiple devices. Last spring, Pricefx announced plug-and-play integrations between its CPQ software and the industry’s leading enterprise-grade customer relationship management (CRM) solutions, including Salesforce, Microsoft Dynamics 365 and SAP Cloud for Customer.

“In 2019, Pricefx continued to deliver a fast, flexible and friendly pricing solution to enterprises looking to increase revenue and profits,” said Patrick Adams, chief revenue officer of Pricefx. “Investor support, industry accolades, customer wins and new product innovation point to strong demand for Pricefx’s true cloud-native pricing platform. We are excited about 2019’s results and expect to continue our amazing growth into 2020 with expanded adoption of the platform and new solutions designed to give our customers a competitive edge.”

In Q1 2020, Pricefx Advantage, the company’s new partner program, will officially launch. The program seeks to create a connected ecosystem of pricing strategists, system integrators and Independent Software Vendors (ISV’s) who will team with Pricefx to help customers achieve pricing superiority at scale, faster than anyone else in the market.

Follow Pricefx
Blog: https://www.pricefx.com/site/blog/
Twitter: https://twitter.com/price_fx
LinkedIn: https://www.linkedin.com/company/price-f-x-/

About Pricefx

Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

Gartner Disclaimer: Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye